Search Results
Results found for "Shane Wright"
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
in Boston, the GPCR Drug Discovery track will deliver breakthroughs, bold ideas, and the strategies shaping GPCR , our mission is simple: connect the GPCR community, share knowledge, and accelerate innovation We’re helping shape the conversation. 🚀 Why GPCRs Are Still the Hottest Target Class in Drug Discovery
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
Without a reversal agent for xylazine, the best defense right now is mechanistic understanding .
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Rodriguez, P.J., et al., Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Chemistry Frontiers 2025 , a conference organized by both the EFMC and the ACSMEDI, in an effort to share She has a lot of experience working for bigger businesses which she now shares as an advisor for startups Sharing the round table discussion with these excellent scientists felt like a dream come true, and Maria This Chemistry Tools session was more industry focused than those before, and Maria shared the floor This was a very enriching experience for Maria, not only did she have a chance to share Celtarys’ technology
- 📰 GPCR Weekly News, September 18 to 24, 2023
Bioscience Announces Site Relocation AI can help to speed up drug discovery — but only if we give it the right
- Advantages of Fluorescent Probes in GPCR Assays
Our scientific team can guide you choose or design the right fluorescent ligand for your research.
- 📰 GPCR Weekly News, January 1 to 7, 2024
Officer Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights
- 📰 GPCR Weekly News, June 3 to June 9, 2024
More details will be shared soon, and registration will open in July 2024. Dr. GPCR Event Highlight We are thrilled to share the news of our in-person event in partnership with the binding genes unveiled via RNA polymerase II degradation Growth factor-dependent phosphorylation of Gαi shapes
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
News from November 25th to December 1st, 2024 Industry News Amgen says obesity drug caused up to 20% weight
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Let’s keep fostering a collaborative environment for sharing ideas and expanding knowledge! The presentations and discussions sparked new ideas and collaborations, shaping the future of the field
- Addex Raises $10 Million In Equity Financing
a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (“ADSs”) at a gross purchase price of $6.50 per ADS , which is equivalent to CHF 1.00 per share. Each ADS represents six shares. the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares
- From Pipettes to Platforms: The Evolution of GPCR Research
They shaped how questions were asked. Leadership, Luck, and the Lab The episode isn’t just about technology — it’s also about how careers are shaped And those who understand both the legacy and the future of GPCR work are the ones shaping the next era
- Addex raises $4.2 million in equity financing
in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS , which is equivalent to CHF 0.27 per share. Each ADS represents six shares. agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
of GPCR-targeted drugs fail—not because of poor chemistry, but because we’ve misunderstood how these shape-shifting
- Understanding Orthosteric Binding: The Key to Drug Action
The receptor may change shape upon binding, affecting how the drug interacts and how effective it will The dynamic interplay of chemical forces shapes drug effectiveness.
- Breaking the Myth of High and Low Affinity Sites
Yet some assumptions still shaping pharmacology workflows haven’t evolved as fast as today’s science. The analytical tools that shaped traditional affinity analysis were designed for simpler systems.
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics.
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
This simple advice, passed on to Ben in grad school, has helped him stay sane, focused, and impactful Imposter Syndrome and Finding Your Place Ben shares the moment he realized he mattered, when he was
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Randy Hall's study: GPR37L1's role in shaping cortical astrocytes during development Dr. Want to share your project informally? Submit a 1-minute abstract video using this form.
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
The natural ligand of the target receptor provides an excellent scaffold, already with a size and shape Right: Orion ligand analogs are engineered to optimize transmembrane domain providing significantly increased Orion’s PROcisionXᵀᴹ Platform In Orion’s discovery process, shape space at the TM domain ‘message’ site Since shape space exploration is specifically focused on the ‘message’ site in the TM domain, this means
- Sign Up Now!
GPCR Summit from October 10th to the 16th is taking shape.
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Terry Kenakin Monthly Ask-Me-Anything sessions A growing, curated on-demand library Opportunities to shape Scientists acting on today’s insight will shape tomorrow’s breakthroughs. 40 years of expertise at your
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
. ✅ Practical insight into how enzyme activation and inhibition shape drug safety, efficacy, and design a molecule directly blocks the substrate’s access) from allosteric inhibition, which alters enzyme shape toughest pharmacology questions — from receptor bias and assay design to enzyme kinetics — and help shape
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
So I designed my own PhD program,” Sokhom shared.
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
realization was that these small, single-transmembrane proteins weren’t just chaperones; they actively shaped
- New Podcast, Sweet Structures & $2.2B GPCR Moves
A new commentary highlights how detergents and cholesterol shape mGluR2 activation—no ligand required
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
. 🔍 Quick Wins This Week 🔹 Tell us what matters → News Survey Your 1-minute feedback shapes what
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
In this episode, Catherine reflects on how her identity as a scientist took shape, why she’s committed That kind of street-level data shapes everything: dosing strategies that reflect actual potencies in
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share




















